Novartis announced that a Phase 3 trial of QMF149 in patients with uncontrolled asthma has met its primary endpoint.
The drugmaker showed the drug combination (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) is better at improving lung function than indacaterol acetate and mometasone furoate alone.
If approved, medium and high dose QVM149 could be beneficial for people with asthma who are still uncontrolled after being treated with the established standard of care - medium and high dose long-acting beta agonist/inhaled corticosteroid.
Novartis filed for approval of the drug in the EU earlier this year
Read the press release
